Jefferies keeps EUR 55.00 target for Fresenius stock

Published on 10/13/2026 at 13:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 6.00 percent to EUR 5.864 billion. Fresenius stock costs EUR 43.22 on October 13, 2026, 0.51 percent above Xetra close.

Jefferies analyst James Vane maintained a Buy rating and set a EUR 55.00 target on October 5, 2026.
Fresenius reported second-quarter 2026 revenue of EUR 5.864 billion, up 6.00 percent.
Fresenius stock was trading at EUR 43.22 at Lang & Schwarz on October 13, 2026 at 1:48 p.m. CEST, 0.51 percent above the Xetra close of October 12, 2026 at EUR 43.00.
Fresenius has scheduled its third-quarter 2026 conference call for November 4, 2026, with market capitalization at EUR 24.3 billion.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Jefferies analyst James Vane maintained a Buy rating on Fresenius and set a EUR 55.00 price target on October 5, 2026, according to Markets Insider. The target lies 27.26 percent above the EUR 43.22 price from Lang & Schwarz. Fresenius stock was trading at EUR 43.22 on October 13, 2026 at 1:48 p.m. CEST, 0.51 percent above the Xetra close of October 12, 2026 at EUR 43.00.

Revenue rises in second quarter

Fresenius reported EUR 5.864 billion in revenue for the second quarter of 2026, an increase of 6.00 percent from EUR 5.571 billion in the second quarter of 2025, according to Fresenius. The company also reported consolidated EBIT of EUR 719 million, up 10.00 percent from EUR 654 million in the year-earlier quarter.

Core net income reached EUR 470 million in the second quarter of 2026, up 14.00 percent from EUR 412 million. Core earnings per share rose 14.00 percent to EUR 0.83 from EUR 0.73, giving the analyst target a backdrop of higher recent operating earnings.

Price stays below yearly high

The Lang & Schwarz price stood EUR 9.74 below Fresenius' 52-week high of EUR 52.96 and EUR 8.11 above its 52-week low of EUR 35.11 on October 13, 2026. That places the stock 18.39 percent below the high and 23.06 percent above the low.

Trading volume was 188,573 shares at the latest finance-data timestamp, compared with an average volume of 999,197 shares. The current quote therefore represented 18.87 percent of the reported average volume at that point.

Valuation and next date

Fresenius had a market capitalization of EUR 24.3 billion and a price-to-earnings ratio of 15.70 as of October 13, 2026. The company has scheduled its conference call on third-quarter 2026 results for November 4, 2026, according to Fresenius.

Comparison with peers

Fresenius (Xetra, EUR): plus 0.51 percent, price-to-earnings ratio 15.70, market capitalization EUR 24.3 billion
Siemens Healthineers (Xetra, EUR): plus 0.71 percent, price-to-earnings ratio 20.16, market capitalization EUR 44.7 billion
Fresenius Medical Care (NYSE, USD): plus 0.71 percent, price-to-earnings ratio 11.47, market capitalization USD 11.4 billion

Price and trading frame

Fresenius stock was trading at EUR 43.22 at Lang & Schwarz on October 13, 2026 at 1:48 p.m. CEST, 0.51 percent above the Xetra close of October 12, 2026 at EUR 43.00. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.